CRISPR Gene-Therapy: A Critical Review of Ethical Concerns and a Proposal for Public Decision-Making
Research output: Contribution to journal › Review › Research › peer-review
Standard
CRISPR Gene-Therapy : A Critical Review of Ethical Concerns and a Proposal for Public Decision-Making. / Lange, Victor; Kappel, Klemens.
In: Canadian Journal of Bioethics, Vol. 5, No. 2, 2022, p. 78-87.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - CRISPR Gene-Therapy
T2 - A Critical Review of Ethical Concerns and a Proposal for Public Decision-Making
AU - Lange, Victor
AU - Kappel, Klemens
N1 - Publisher Copyright: © Victor Lange and Klemens Kappel, 2022.
PY - 2022
Y1 - 2022
N2 - CRISPR is currently viewed as the central tool for future gene therapy. Yet, many prominent scientists and bioethicists have expressed ethical concerns around CRISPR gene therapy. This paper provides a critical review of concerns about CRISPR gene therapy as expressed in the mainstream academic literature, paired with replies also generally found in that literature. The expressed concerns can be categorised into three types depending on whether they stress risk/benefit ratio, autonomy and informed consent, or concerns related to various aspects of justice. In the reviewed literature, we found no intrinsic objections to CRISPR gene therapy, even though many such objections were present in discussions of gene editing in the 1990s. The paper then proposes a brief outline for a practically applicable moral framework for public decision-making about CRISPR gene therapy and suggests how such a framework might be supported. We also suggest that this framework should govern public engagement about CRISPR gene therapy in order to reduce the risk that we make decisions about CRISPR gene therapy based on misperceptions, inflated views of risk, or unreasonable moral or religious views.
AB - CRISPR is currently viewed as the central tool for future gene therapy. Yet, many prominent scientists and bioethicists have expressed ethical concerns around CRISPR gene therapy. This paper provides a critical review of concerns about CRISPR gene therapy as expressed in the mainstream academic literature, paired with replies also generally found in that literature. The expressed concerns can be categorised into three types depending on whether they stress risk/benefit ratio, autonomy and informed consent, or concerns related to various aspects of justice. In the reviewed literature, we found no intrinsic objections to CRISPR gene therapy, even though many such objections were present in discussions of gene editing in the 1990s. The paper then proposes a brief outline for a practically applicable moral framework for public decision-making about CRISPR gene therapy and suggests how such a framework might be supported. We also suggest that this framework should govern public engagement about CRISPR gene therapy in order to reduce the risk that we make decisions about CRISPR gene therapy based on misperceptions, inflated views of risk, or unreasonable moral or religious views.
KW - biotechnology
KW - convergence
KW - CRISPR
KW - gene therapy
KW - mid-level principles
KW - public engagement
UR - http://www.scopus.com/inward/record.url?scp=85133866676&partnerID=8YFLogxK
U2 - 10.7202/1089787ar
DO - 10.7202/1089787ar
M3 - Review
AN - SCOPUS:85133866676
VL - 5
SP - 78
EP - 87
JO - Canadian Journal of Bioethics
JF - Canadian Journal of Bioethics
SN - 1923-2799
IS - 2
ER -
ID: 320488289